In 2025, the budget for the state healthcare system of Latvia was set at €1,701,080,584, which is 2.4% more than in 2024. This is evidenced by the annual public report of the National Health Service (NVD). A total of €1.701 billion was allocated for the healthcare program last year, of which €1.697 billion was actually spent, or 99.8% of the available funding. Compared to 2024, actual expenditures increased by approximately €43 million, or 2.6%. The largest expense category was the provision of emergency medical care in hospitals. For this purpose, €450.01 million was allocated, which is €3.03 million, or 0.7%, more than the previous year. The increase in expenditures is mainly related to the funding of the hospital network development and ensuring the continuity of medical care in hospital emergency departments, including strengthening the work of emergency and patient admission departments. The volume of expenditures was also influenced by the provision of medical care to the civilian population of Ukraine residing in Latvia. A total of €366.23 million was spent on other outpatient medical services, which is €2.83 million, or 0.8%, less than in 2024. Additional funding in this program was directed towards the development of integrated and multidisciplinary outpatient care for patients with inflammatory bowel diseases, as well as improving access to medical services for minors abusing psychoactive substances. Furthermore, funds were used to settle accounts with European Union and European Economic Area countries for medical services provided to residents of Latvia abroad. In 2025, the National Health Service received bills totaling €23,963,559 for the treatment of residents of Latvia in EU countries, the European Economic Area, Switzerland, and the United Kingdom. Of this amount, €8,981,809 was billed for necessary medical care provided under the European Health Insurance Card or a substitute certificate, €9,591,838 for the full volume of medical care, and another €5,389,912 for planned treatment. In turn, the NVD issued bills to foreign partners totaling €1,272,979 for medical services provided in Latvia to citizens insured in EU countries, the EEA, Switzerland, and the United Kingdom. A total of €320.65 million was allocated for the payment of reimbursable medications and medical devices. Compared to 2024, actual expenditures increased by €35.05 million, or 12.3%. The increase in expenditures is associated with the development of the medication reimbursement system, expanding access to medications for patients, and increasing treatment options for people with rare diseases. Funds were also directed towards the payment for new medications, expanding reimbursement conditions for those already included in the list of medications, and implementing a new model for setting the trade markup on medications. A total of €238.84 million was spent on planned inpatient medical care, which is €5.1 million, or 2.3%, less than the previous year. The decrease in expenditures is explained by the fact that in 2024, hospitals were allocated one-time funding to cover fixed payments under the DRG system, but such funds were not provided in 2025. A total of €225.67 million was allocated for primary outpatient medical care. Compared to the previous year, expenditures increased by €7.68 million, or 3.5%. Additional funds were allocated for maintaining family doctor practices, attracting additional staff, replacing medical workers during their justified absence, developing pediatric dental care, and improving medical services for residents of long-term social care and social rehabilitation institutions. A total of €64.23 million was spent on outpatient laboratory tests, which is €4.41 million, or 7.4%, more than in 2024. Additional funding was directed towards improving the diagnosis of rare diseases and transplantation processes, expanding laboratory biomarker determination in oncology, preserving reproductive material of patients before undergoing chemotherapy, and paying for laboratory tests performed beyond the volumes specified in contracts with medical institutions. A total of €28.31 million was spent on centralized procurement of medications and medical materials, which is €2.43 million, or 9.4%, more than the previous year. The increase in expenditures was mainly supported by additional funds for vaccinating children and adolescents aged 12 to 17 against human papillomavirus, purchasing whooping cough vaccines for pregnant women and adolescents, as well as acquiring vaccines against pneumococcal infections. From the contingency funds, €59.68 million was used last year, which is €34.23 million, or 134.5%, more than in 2024. Of this amount, €32.37 million was directed towards partial settlements with EU countries, the European Economic Area, Switzerland, and the United Kingdom for medical services provided to residents of Latvia. Another €10.78 million was used to cover the funding deficit for reimbursable medications and ensure continuity of treatment, and €6.01 million was allocated for the work of mobile palliative care teams for patients at home. The report from the National Health Service shows that in 2025, the state continued to increase healthcare funding, with particular attention to the development of hospitals, expanding the medication reimbursement program, supporting family doctors, improving diagnostics and vaccination, as well as ensuring access to medical care both in Latvia and abroad.